Dual-purpose package allows submission in both paper and electronic formats
Dual-purpose package allows submission in both paper and electronic formats
Thomson Scientific (Philadelphia, PA, and London, UK) recently released the latest version of its regulatory compliance tool, InSight Publisher version 3.5. The latest iteration enables pharmaceutical companies to create, manage, and publish regulatory submissions in both paper and electronic form using a single software application, potentially saving critical time in the drug development process.
Around the world, regulatory authorities increasingly prefer the electronic format, yet they still require a paper version. With Liquent InSight version 3.5, life science professionals can produce both from a single assembly, using the same thin-client application integrated with the rest of the InSight software suite. Since it is built on the same platform as InSight Manager, which offers registration management and submission tracking capabilities, the entire platform is highly adaptable to different organizational processes and designs.
Thomson Scientific, (215) 386-0100, www.liquent.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.